A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

Stopped early · Phase 1

Conditions studied: Solid Tumor, Adult

In brief

This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading solid tumors. The main objective is to identify the highest tolerable dose or the highest administered dose of BGB-24714. Additionally, the study aims to identify the most suitable doses for further investigation in larger groups of participants.

Key facts

Study ID
NCT05381909
Run by
BeiGene
People needed
157
Starts
2022-07-06
Expected to finish
2025-07-25
Last updated by the study team
2026-02-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.